Pivekimab sunirine-pvzy

Brand names: Decnupaz · Active ingredient: Pivekimab Sunirine

In short: DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Forms & strengthsFor injection: 2 mg of pivekimab sunirine-pvzy as a white to off-white, lyophilized cake in a single-dose vial.
LabelAbbVie Inc.
Label updatedJun 01, 2026

What is Pivekimab sunirine-pvzy used for?

DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

âš  Boxed warning (FDA's strongest warning)

DECNUPAZ can cause hepatotoxicity, including severe or fatal hepatic VOD (also known as sinusoidal obstruction syndrome)

.

Closely monitor patients for signs and symptoms of VOD including elevations in liver tests, hepatomegaly (which may be painful), rapid weight gain, and ascites

.

Monitor liver tests, including ALT, AST, and total bilirubin, prior to each dose of DECNUPAZ

.

Delay DECNUPAZ dosage for liver test elevation. Permanently discontinue DECNUPAZ for patients who experience VOD

.

Pivekimab sunirine-pvzy dosage

DECNUPAZ requires reconstitution followed by two dilutions prior to administration.

Read the entire preparation instructions carefully before preparing and administering DECNUPAZ.

The recommended dose of DECNUPAZ in adult patients with BPDCN is 0.045 mg/kg intravenously over approximately 15-30 minutes once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Calculate the dose based on the patient’s actual body weight .

Administer the premedications in Table 1 the day prior to and the day of the infusion of DECNUPAZ to reduce the risk of infusion-related reactions (IRRs) .

Administration Time

P

rior to

DECNUPAZ

Infusion | Premedication | Route of Administration | Dose

(

or equivalent)

Day before DECNUPAZ infusion | Corticosteroid | Oral or intravenous | Dexamethasone 8 mgtwice daily

30 to 60 minutes prior to infusion | Corticosteroid | Intravenous | Dexamethasone 8 mg

Antihistamine | Intravenous | Diphenhydramine 25 mg to 50 mg

Antipyretic | Oral | Acetaminophen 325 mg to 650 mg

Table 2 provides recommended dosage modifications for DECNUPAZ due to adverse reactions.

Adverse Reaction | Severity of Adverse Reaction

a | Dose Modification Guidelines

Veno-occlusive disease (VOD)

| Any Grade | Permanently discontinue DECNUPAZ

Increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT) | Either AST or ALT is >2.5 x ULN | Delay further DECNUPAZ dosing until AST or ALT have returned to ≤2.5 × ULN

Increased bilirubin | Total bilirubin > 1.5 × ULN | Delay further DECNUPAZ dosing until total bilirubin has returned to ≤1.5 × ULN

Infusion-related reactions | Grade 2 | Interrupt DECNUPAZ infusion and institute appropriate medical management

After full resolution of symptoms, resume DECNUPAZ infusion at 50% of the previous rate and if no further symptoms appear, increase rate as appropriate until infusion is completed

Grade 3 | Stop DECNUPAZ infusion and institute appropriate medical management

After full resolution of symptoms, resume the infusion at 50% of the previous rate

If symptoms recur, permanently discontinue

Grade 4 | Permanently discontinue DECNUPAZ

Edema | Grade 1 (5-10% inter-limb discrepancy in volume or circumference,4 kg weight gain, or 1+ pitting edema (2 mm)) | Follow weekly weights

Consider administering diuretic therapy

Grade 2 (10-30% inter-limb discrepancy in volume or circumference, >4 kg weight gain, or 2+ pitting edema (4 mm)) | Administer diuretic therapy

Manage hypoalbuminemia as needed

Delay further DECNUPAZ dosing until edema has returned to Grade 0-1 or baseline

If delayed more than 2 weeks, consider dose reduction before resuming

Grade 3 (> 30% inter-limb discrepancy in volume, or 3+/4+ pitting edema (>6 mm)) | Consider combination diuretic therapy

Manage hypoalbuminemia as needed

Delay …

How to take Pivekimab sunirine-pvzy — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Veno-occlusive Disease (VOD)

Advise patients that DECNUPAZ can cause VOD. Advise patients to immediately contact their healthcare provider if they experience symptoms of VOD, which may include jaundice, rapid weight gain, dark urine, and abdominal pain or distention. Inform patients that liver problems may require dosing interruption or permanent discontinuation of DECNUPAZ .

Infusion-Related Reactions

Advise patients that DECNUPAZ can cause infusion-related reactions. Advise patients to immediately contact their healthcare provider for any signs or symptoms of infusion-related reactions, which may include chills, tachycardia, hypotension, fever, tachypnea, and dyspnea .

Edema

Advise patients that DECNUPAZ can cause edema. Advise patients to contact their healthcare provider if they experience swelling, weight gain, shortness of breath or difficulty breathing, or fluid retention .

Sulfite Allergic Reactions

Advise patients about potential for sulfite sensitivity. …

Warnings & precautions

Do not take this medicine if: None.

DECNUPAZ can cause hepatotoxicity, including VOD, a severe form of hepatotoxicity. In CADENZA, VOD occurred in 6% (7/116) of adult patients during treatment or following a subsequent hematopoietic stem cell transplantation (HSCT). Of the 7 total patients who developed VOD, 3 patients had treatment-naïve BPDCN and 4 patients had relapsed/refractory BPDCN. Among all 116 patients treated with DECNUPAZ at 0.045 mg/kg, VOD occurred in 2/116 (2%) during treatment, with onset up to 30 days after the last dose. Among 19 patients with BPDCN who proceeded to HSCT, VOD occurred in 5/19 patients (26%), including two fatal cases. The median time from subsequent HSCT to onset of VOD was 11 days (range: 7 – 25 days).

After receiving DECNUPAZ, patients should be closely monitored for signs and symptoms of VOD including elevations in ALT, AST, total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. Monitor liver tests, including ALT, AST, and total bilirubin, prior to each dose of DECNUPAZ. Based on elevations of liver tests, delay DECNUPAZ. In patients who experience VOD, discontinue DECNUPAZ and treat according to standard medical practice .

DECNUPAZ can cause serious, life-threatening infusion-related reactions (IRR); signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. In CADENZA, IRRs occurred in 26% (30/116) of patients during treatment with DECNUPAZ at 0.045 mg/kg once every three weeks, including Grade 1 in 4.3% (5/116), Grade 2 in 16% (19/116), and Grade 3 in 5% (6/116) of patients. IRR occurred in Cycle 1 in 25% (29/116) of patients with decreasing frequency in subsequent cycles. IRR led to discontinuation in one patient. …

Pivekimab sunirine-pvzy side effects

The following clinically significant adverse reactions are discussed elsewhere in the labeling:

Hepatotoxicity, Including Hepatic VOD (also known as Sinusoidal Obstruction Syndrome)

Infusion-Related Reactions

Edema

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of DECNUPAZ was evaluated in CADENZA, a single-arm, open-label study that included 116 adults with newly diagnosed or relapsed/refractory myeloid malignancies, including 84 with BPDCN, treated with DECNUPAZ 0.045 mg/kg once every three weeks.

The median number of cycles administered was 3 (range: 1 to 34) in the overall population, and 3.5 (range: 1 to 34) in patients with BPDCN.

Serious adverse reactions occurred in 55% of patients treated with DECNUPAZ. The most common (≥2%) serious adverse reactions were febrile neutropenia, pneumonia, edema, sepsis, hemorrhage, thrombosis, infusion-related reactions, viral infection, pneumonitis, infections without specified pathogens, pyrexia, and musculoskeletal pain. Fatal adverse reactions occurred in 4.3% of patients who received DECNUPAZ, including cardiac arrest (0.9%), clostridium difficile infection (0.9%), failure to thrive (0.9%), depressed level of consciousness (0.9%), and respiratory failure (0.9%). …

Drug interactions

Strong

and moderate

CYP3A inhibitors

Closely monitor patients for adverse reactions with DECNUPAZ when used concomitantly with strong and moderate CYP3A inhibitors.

FGN849 is a substrate of CYP3A . Concomitant use of DECNUPAZ with strong and moderate CYP3A inhibitors may increase unconjugated FGN849 exposure, which may increase the risk of DECNUPAZ adverse reactions.

About this medicine

Pivekimab sunirine-pvzy is a CD123-directed antibody and alkylating agent conjugate created by conjugating the IgG1 monoclonal antibody G4723A to the DGN549C linker-payload. The antibody-drug conjugate (ADC) contains approximately two DGN549C molecules sulfonated prior to conjugation and bound to the heavy chains (HC) of the G4723A antibody. Pivekimab sunirine-pvzy has an approximate molecular weight of 148 kDa. Pivekimab sunirine-pvzy is produced by site directed chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis.

Pivekimab sunirine-pvzy has the following structure:

DECNUPAZ (pivekimab sunirine-pvzy) for injection is a sterile, lyophilized cake in a single-dose vial for reconstitution and dilution. DECNUPAZ is supplied as 2 mg per vial and requires reconstitution with Sterile Water for Injection, USP (1.1 mL) to obtain a concentration of 2 mg/mL. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 508b6ff8-601d-4901-a7a5-816141134054. Read the full official label on DailyMed.